CASI Pharmaceuticals COO Chunhua Wang's Stock Option Holdings Disclosure

This SEC Form 3 filing discloses the initial beneficial ownership of stock options by Chunhua Wang, Chief Operating Officer of CASI Pharmaceuticals, Inc. The filing reports Wang's holdings of 14 stock option grants with varying expiration dates from 2028 to 2034. The options cover a total of 200,000 ordinary shares with exercise prices ranging from $1.93 to $5.78 per share. All options are fully vested and exercisable as of the filing date. The filing indicates direct ownership of these derivative securities and was signed on April 3, 2026, with a reporting period ending March 18, 2026. This represents standard disclosure of executive compensation in the form of equity awards.